Open Nav

BioVaxys LLC

Seeking additional investment partners for the Phase I/II clinical trial

  • Date:Thursday, October 18
  • Time:2:00 PM - 2:15 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Founded in 2018, BioVaxys LLC is a clinical-stage immuno-oncology company developing a universal vaccine platform for individualized cancer treatment of resectable solid tumors. Based on multihaptenized autologous vaccine technology developed by BioVaxys founder Dr David Berd, BioVaxys will initially be targeting ovarian cancer, melanoma, and other resectable solid tumors.
  • Company
  • Company HQ City:Radnor
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • CEO/Top Company Official:Kenneth Kovan
  • Year Founded:2018
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :BVX-001
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:A unique aspect of the BioVaxys business model is our leveraging the extensive know-how and clinical experience from prior development of an autologous haptenized vaccine by Avax Technologies, Inc. ~$100M was invested into Avax, but for various business reasons (NOT related to the science or vaccine clinical development) the company ceased operations. Biovaxys has assembled the core IP and the former team, and is developing a novel---and we believe superior---approach that has been significanty de-risked by the prior development efforts.
  • Previous and Current Investors:Firebird Global Management LLC
  • Total Amount Raised to Date, In All Rounds:$1M